Delving into the Latest Updates on 18F-Fluoroazomycin Arabinoside with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms

Target-

Mechanism-

Therapeutic Areas

NeoplasmsRespiratory Diseases

Active Indication

Lung Cancer

Inactive Indication

Breast Ductal CarcinomaGlioblastoma MultiformeHypoxia+ [5]

Originator Organization

University Health Network

Active Organization

University Health Network

Inactive Organization

AHS Cancer Control Alberta

Drug Highest PhaseClinical

First Approval Date-

Regulation-

Login to view timeline

This is a single arm, single centre, investigator initiated study to investigate the use of FAZA-PET in combination with MRI. FAZA is an investigational radiotracer used in PET scans. FAZA PET-MRI will be used to measure hypoxia in up to 20 patients with unresectable, non-metastatic, locally advanced un-resectable pancreatic adenocarcinoma (LAPAC).
After each FAZA PET-MRI scan, patients will be followed up via telephone, 48 hours after the imaging session to assure that the procedure was tolerated without side effects. Patients will undergo a FAZA PET-MRI scans before and after their standard of care radiation treatment.

Start Date18 May 2021

Sponsor / Collaborator

University Health Network

NCT04409314 / CompletedNot ApplicableIIT

Pilot Study of Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-Cell Therapy

This study evaluates whether tumors present in patients with cancer who are planned to get CAR T-cells have low amounts of oxygen (hypoxia). PET scans may be used to check the amounts of oxygen within areas of cancer with a special radioactive tracer called FAZA that specifically looks for areas of low oxygen. This study is being done to help researchers determine how the amount of oxygen within areas of cancer affect how well CAR T-cells kill cancer cells.

Start Date16 Apr 2020

Sponsor / Collaborator

The University of California, San Francisco

100 Clinical Results associated with 18F-Fluoroazomycin Arabinoside

Login to view more data

100 Translational Medicine associated with 18F-Fluoroazomycin Arabinoside

Login to view more data

100 Patents (Medical) associated with 18F-Fluoroazomycin Arabinoside

Login to view more data

29

Literatures (Medical) associated with 18F-Fluoroazomycin Arabinoside

01 Sep 2023·European journal of nuclear medicine and molecular imaging

Hypoxia-specific imaging in patients with lymphoma undergoing CAR-T therapy.

Article

Author: Ahmadi, Michael ; Spinner, Michael ; Huang, Chiung-Yu ; Fakhri, Bita ; Leonard, Michelle K ; Wang, Victoria ; Pampaloni, Miguel Hernandez ; Seshadri, Madhav Rao ; Banerjee, Rahul ; Pandita, Divita ; Andreadis, Charalambos Babis ; LaRue, Siobhan ; Ai, Weiyun Z ; Kaplan, Lawrence

PURPOSEIntratumoral hypoxia in non-Hodgkin's Lymphoma (NHL) may interfere with chimeric antigen receptor T-cell (CAR-T) function. We conducted a single-center pilot study (clinicaltrials.gov ID NCT04409314) of [¹⁸F]fluoroazomycin arabinoside, a hypoxia-specific radiotracer abbreviated as [¹⁸F]FAZA, to assess the feasibility of this positron emission tomography (PET) imaging modality in this population.METHODSPatients with relapsed NHL being evaluated for CAR-T therapy received a one-time [¹⁸F]FAZA PET scan before pre-CAR-T lymphodepletion. A tumor to mediastinum (T/M) ratio of 1.2 or higher with regard to [¹⁸F]FAZA uptake was defined as positive for intratumoral hypoxia. We planned to enroll 30 patients with an interim futility analysis after 16 scans.RESULTSOf 16 scanned patients, 3 had no evidence of disease by standard [¹⁸F]fluorodeoxyglucose PET imaging before CAR-T therapy. Six patients (38%) had any [¹⁸F]FAZA uptake above background. Using a T/M cutoff of 1.20, only one patient (a 68-year-old male with relapsed diffuse large B-cell lymphoma) demonstrated intratumoral hypoxia in an extranodal chest wall lesion (T/M 1.35). Interestingly, of all 16 scanned patients, he was the only patient with progressive disease within 1 month of CAR-T therapy. However, because of our low overall proportion of positive scans, our study was stopped for futility.CONCLUSIONSOur pilot study identified low-level [¹⁸F]FAZA uptake in a small number of patients with NHL receiving CAR-T therapy. The only patient who met our pre-specified threshold for intratumoral hypoxia was also the only patient with early CAR-T failure. Future plans include exploration of [¹⁸F]FAZA in a more selected patient population.

01 Feb 2023·Nuclear Medicine and Molecular Imaging

Kinetic Evaluation of the Hypoxia Radiotracers [18F]FMISO and [18F]FAZA in Dogs with Spontaneous Tumors Using Dynamic PET/CT Imaging

Article

Author: Chaudhari, Abhijit J ; Choen, Sangkyung ; Kent, Michael S ; Cherry, Simon R ; Krtolica, Ana ; Zwingenberger, Allison L

AbstractPurposeWe evaluated the kinetics of the hypoxia PET radiotracers, [18F]fluoromisonidazole ([18F]FMISO) and [18F]fluoroazomycin-arabinoside ([18F]FAZA), for tumor hypoxia detection and to assess the correlation of hypoxic kinetic parameters with static imaging measures in canine spontaneous tumors.MethodsSixteen dogs with spontaneous tumors underwent a 150-min dynamic PET scan using either [18F]FMISO or [18F]FAZA. The maximum tumor-to-muscle ratio (TMRmax) > 1.4 on the last image frame was used as the standard threshold to determine tumor hypoxia. The tumor time-activity curves were analyzed using irreversible and reversible two-tissue compartment models and graphical methods. TMRmax was compared with radiotracer trapping rate (k3), influx rate (Ki), and distribution volume (VT).ResultsTumor hypoxia was detected in 7/8 tumors in the [18F]FMISO group and 4/8 tumors in the [18F]FAZA group. All hypoxic tumors were detected at > 120 min with [18F]FMISO and at > 60 min with [18F]FAZA. [18F]FAZA showed better fit with the reversible model. TMRmax was strongly correlated with the irreversible parameters (k3 and Ki) for [18F]FMISO at > 90 min and with the reversible parameter (VT) for [18F]FAZA at > 120 min.ConclusionsOur results showed that [18F]FAZA provided a promising alternative radiotracer to [18F]FMISO with detecting the presence of tumor hypoxia at an earlier time (60 min), consistent with its favorable faster kinetics. The strong correlation between TMRmax over the 90–150 min and 120–150 min timeframes with [18F]FMISO and [18F]FAZA, respectively, with kinetic parameters associated with tumor hypoxia for each radiotracer, suggests that a static scan measurement (TMRmax) is a good alternative to quantify tumor hypoxia.

01 Feb 2021·European Journal of Nuclear Medicine and Molecular ImagingQ1 · MEDICINE

The role of 18F-FAZA PET/CT in detecting lymph node metastases in renal cell carcinoma patients: a prospective pilot trial

Q1 · MEDICINE

Article

Author: Picchio, Maria ; Bernardi, Rosa ; Gianolli, Luigi ; Montorsi, Francesco ; Doglioni, Claudio ; Bettinardi, Valentino ; Trevisani, Francesco ; Necchi, Andrea ; Mapelli, Paola ; Incerti, Elena ; Monterisi, Cristina ; Cascinu, Stefano ; Larcher, Alessandro ; Capitanio, Umberto ; Lucianò, Roberta ; Pepe, Gino ; Bertini, Roberto ; Salonia, Andrea

BACKGROUNDThe accurate detection of nodal invasion is an unmet need in the clinical staging of renal cancer. Positron emission tomography (PET) with 18F-fluoroazomycin arabinoside (18F-FAZA), a hypoxia specific tracer, is a non-invasive imaging method that detects tumour hypoxia. The aim of this work was to evaluate the role of 18F-FAZA PET/CT in the identification of lymph node metastases in renal cancer.METHODSA proof-of-concept phase 2 study including 20 kidney cancer patients ( ClinicalTrials.gov Identifier: NCT03955393) was conducted. Inclusion criteria were one or more of the following three criteria: (1) clinical tumour size > 10 cm, (2) evidence of clinical lymphadenopathies at preoperative CT scan and (3) clinical T4 cancer. Before surgery, 18F-FAZA PET/CT was performed, 2 h after the intravenous injection of the radiotracer. An experienced nuclear medicine physician, aware of patient's history and of all available diagnostic imaging, performed a qualitative and semi-quantitative analysis on 18F-FAZA images. Histopathological analysis was obtained in all patients on surgical specimen.RESULTSFourteen/19 (74%) patients had a non-organ confined renal cell carcinoma (RCC) at final pathology (either pT3 or pT4). Median number of nodes removed was 12 (IQR 7-15). The rate of lymph node invasion was 16%. No patient with pN1 disease showed positive 18F-FAZA PET, thus suggesting the non-hypoxic behaviour of the lesions. In addition, neither primary tumour nor distant metastases presented a pathological 18F-FAZA uptake. No adverse events were recorded during the study.CONCLUSIONS18F-FAZA PET/CT scan did not detect RCC lymph neither nodal nor distant metastases and did not show any uptake in the primary renal tumour.

100 Deals associated with 18F-Fluoroazomycin Arabinoside

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Lymphoma	Phase 3	CA	AHS Cancer Control Alberta	12 Sep 2006
Breast Ductal Carcinoma	Phase 2	CA	AHS Cancer Control Alberta	28 Nov 2008
Hypoxia	Phase 2	CA	AHS Cancer Control Alberta	28 Nov 2008
Glioblastoma Multiforme	Phase 2	CA	AHS Cancer Control Alberta	12 Sep 2006
Neuroendocrine Tumors	Phase 2	CA	AHS Cancer Control Alberta	12 Sep 2006
Non-Small Cell Lung Cancer	Phase 2	CA	AHS Cancer Control Alberta	12 Sep 2006
Renal Cell Carcinoma	Phase 2	CA	AHS Cancer Control Alberta	12 Sep 2006
Squamous Cell Carcinoma of Head and Neck	Phase 2	CA	AHS Cancer Control Alberta	12 Sep 2006

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


WCLC2016	Not Applicable	Non-Small Cell Lung Cancer	17	18F-Fluoroazomycin Arabinoside (FAZA) (FAZA-PET)	tlxmmzesxw(bzziquswuo) = gkznaflhbg skfxmzcutr (jzhueebggp ) View more	-	06 Dec 2016